+ Follow LETROZOLE Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 626493
[Title] => Right treatments, support system help in healing of breast cancer survivor
[Summary] => “Being diagnosed with breast cancer used to be a death sentence,” says Maris Medina.
[DatePublished] => 2010-11-04 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 322918
[Title] => Letrozole effective as initial post-surgery therapy
[Summary] => A study which was done to compare the efficacy of two drugs for breast cancer showed that letrozole is more effective as an initial therapy after surgery in post-menopausal women with early breast cancer compared with tamoxifen.
The results of Breast International Group 1-98 (BIG 1-98) published in the New England Journal of Medicine showed that letrozole reduced the risk of breast cancer returning by an additional 19 percent over the reduction offered by tamoxifen.
[DatePublished] => 2006-02-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 253305
[Title] => Renewed hope for patients with early breast cancer
[Summary] => Promising new data from a landmark study demonstrated an impressive 40 percent reduction in the risk of distant breast cancer recurrences, or metastases, with extended adjuvant letrozole in post-menopausal women with early breast cancer.
These data were presented during the "Best of Oncology" session in this year’s annual meeting of the American Society of Clinical Oncology (ASCO).
Distant metastases are a well-established risk factor for breast cancer death.
[DatePublished] => 2004-06-10 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 224394
[Title] => Study halted to announce positive results of breast cancer treatment
[Summary] => The study showed breast cancer patients who follow up five years of tamoxifen treatment with letrozole, an estrogen suppressor, cut the risk of recurrence by nearly half.
TORONTO (AP) – Researchers were so encouraged by early results from a study on preventing breast cancer recurrence that they halted their work so more women can benefit from the findings.
[DatePublished] => 2003-10-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
LETROZOLE
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 626493
[Title] => Right treatments, support system help in healing of breast cancer survivor
[Summary] => “Being diagnosed with breast cancer used to be a death sentence,” says Maris Medina.
[DatePublished] => 2010-11-04 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 322918
[Title] => Letrozole effective as initial post-surgery therapy
[Summary] => A study which was done to compare the efficacy of two drugs for breast cancer showed that letrozole is more effective as an initial therapy after surgery in post-menopausal women with early breast cancer compared with tamoxifen.
The results of Breast International Group 1-98 (BIG 1-98) published in the New England Journal of Medicine showed that letrozole reduced the risk of breast cancer returning by an additional 19 percent over the reduction offered by tamoxifen.
[DatePublished] => 2006-02-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 253305
[Title] => Renewed hope for patients with early breast cancer
[Summary] => Promising new data from a landmark study demonstrated an impressive 40 percent reduction in the risk of distant breast cancer recurrences, or metastases, with extended adjuvant letrozole in post-menopausal women with early breast cancer.
These data were presented during the "Best of Oncology" session in this year’s annual meeting of the American Society of Clinical Oncology (ASCO).
Distant metastases are a well-established risk factor for breast cancer death.
[DatePublished] => 2004-06-10 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 224394
[Title] => Study halted to announce positive results of breast cancer treatment
[Summary] => The study showed breast cancer patients who follow up five years of tamoxifen treatment with letrozole, an estrogen suppressor, cut the risk of recurrence by nearly half.
TORONTO (AP) – Researchers were so encouraged by early results from a study on preventing breast cancer recurrence that they halted their work so more women can benefit from the findings.
[DatePublished] => 2003-10-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
November 4, 2010 - 12:00am
February 23, 2006 - 12:00am
October 16, 2003 - 12:00am
